Review on the Comparative Effectiveness of Ketamine and Electroconvulsive Therapy in Treatment-Resistant Depression
DOI:
https://doi.org/10.36283/ziun-pjmd14-4/101Keywords:
Treatment-resistant depression, ketamine, electroconvulsive therapy, meta-analysis, psychiatric treatment, response rates, remissionAbstract
Treatment-resistant depression (TRD) affected nearly 20–30% of individuals diagnosed with major depressive disorder and remained a significant therapeutic challenge. The lack of response to traditional antidepressant therapies placed a substantial emotional, functional, and economic burden on patients and healthcare systems. In recent years, ketamine and electroconvulsive therapy (ECT) emerged as two of the most promising nontraditional interventions for individuals with TRD. Although both treatments demonstrated meaningful antidepressant effects, important differences were observed in their mechanisms, onset of action, durability of response, and safety profiles.
This review aimed to provide a comprehensive comparative overview of ketamine and ECT in the management of TRD, summarizing evidence regarding their clinical efficacy, response and remission rates, and adverse effect profiles. The review also highlighted key clinical considerations, including patient selection criteria, treatment protocols, and practical issues that influenced therapeutic decision-making. By integrating findings from contemporary clinical studies and expert perspectives, this article offered clinicians an informative synthesis to support individualized treatment planning. Ultimately, the review underscored the importance of tailoring interventions to patient needs and contributed insights to improve outcomes for individuals affected by the burden of treatment-resistant depression.
References
1. Al-Harbi, K. S. (2012). Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Preference and Adherence, 6, 369-388.
2. Amos, T. B., Tandon, N., Lefebvre, P., Pilon, D., Kamstra, R. L., Pivneva, I., & Greenberg, P. E. (2018). Direct and indirect cost burden and change of employment status in treatment-resistant depression: A matched-cohort study using a US commercial claims database. Journal of Clinical Psychiatry, 79(2), 17m11725.
3. Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021). Comparative efficacy of racemic ketamine and intranasal esketamine for depression: A systematic review and meta-analysis. Journal of Affective Disorders, 278, 542-555.
4. Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 238-249.
5. Fabbri, C., Corponi, F., Souery, D., Kasper, S., Montgomery, S., Zohar, J., ... & Serretti, A. (2019). The genetics of treatment-resistant depression: A critical review and future directions. International Journal of Neuropsychopharmacology, 22(2), 93-104.
6. Fava, M., & Davidson, K. G. (1996). Definition and epidemiology of treatment-resistant depression. Psychiatric Clinics of North America, 19(2), 179-200.
7. Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., ... & Singh, J. B. (2019). Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: Results of a randomized, double-blind, active-controlled study (TRANSFORM-1). International Journal of Neuropsychopharmacology, 22(10), 616-630.
8. Gaynes, B. N., Lux, L., Gartlehner, G., Asher, G., Forman-Hoffman, V., Green, J., ... & Lohr, K. N. (2020). Defining treatment-resistant depression. Depression and Anxiety, 37(2), 134-145.
9. Kellner, C. H., Greenberg, R. M., Murrough, J. W., Bryson, E. O., Briggs, M. C., & Pasculli, R. M. (2012). ECT in treatment-resistant depression. American Journal of Psychiatry, 169(12), 1238-1244.
10. Petrides, G., Tobias, K. G., Kellner, C. H., & Rudorfer, M. V. (2011). Continuation and maintenance electroconvulsive therapy for mood disorders: Review of the literature. Neuropsychobiology, 64(3), 129-140.
11. Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., ... & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. American Journal of Psychiatry, 163(11), 1905-1917.
12. Semkovska, M., & McLoughlin, D. M. (2010). Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta-analysis. Biological Psychiatry, 68(6), 568-577.
13. Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018). Side-effects associated with ketamine use in depression: A systematic review. Lancet Psychiatry, 5(1), 65-78.
14. Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., ... & Van Nueten, L. (2016). A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. American Journal of Psychiatry, 173(8), 816-826.
15. Wang, Z., Zou, Z., Xiao, J., Min, W., Nan, L. P., Yuan, C., ... & He, Y. (2023). Brain-derived neurotrophic factor blood levels after electroconvulsive therapy in patients with mental disorders: a systematic review and meta-analysis. General Hospital Psychiatry, 83, 86-92.
16. Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., ... & Gould, T. D. (2016). NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 533(7604), 481-486.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
